Director, Value Demonstration & Access Evidence Strategy (Hematology)

pBeOne continues to grow at a rapid pace with challenging and exciting opportunities for experienced professionals. When considering candidates, we look for scientific and business professionals who are highly motivated, collaborative, and most importantly, share our passionate interest in fighting cancer. /p h3Purpose Of The Role /h3 pShape evidence generation decisions during development to maximize future reimbursement, payer negotiations, HTA success and pricing potential. The Director, Value Demonstration Access Evidence Strategy is responsible for designing and implementing global payer and HTA evidence strategies that support successful reimbursement, access and pricing outcomes across the portfolio. The role serves as the strategic bridge between Clinical Development, HEOR, Medical Affairs, Regulatory Affairs and Global Value, Access Pricing (GVAP), ensuring that payer and HTA evidence requirements are incorporated into development programmes as early as possible. The individual will shape integrated evidence plans, anticipate evolving HTA and payer evidence expectations, and ensure that clinical, economic and real-world evidence generation activities support successful Joint Clinical Assessments (JCA), Joint Scientific Consultations (JSC), national HTA submissions, reimbursement negotiations, U.S. payer and value demonstration requirements, and lifecycle management strategies. The role is explicitly accountable for ensuring that U.S. evidence needs are surfaced early, reconciled against ex-U.S. HTA requirements, and reflected as a single, integrated set of requirements in development plans — rather than being raised late or handled separately. /p h3Key Responsibilities /h3 pGlobal Access Evidence Strategy: /p ul liDesign and implement global HTA and payer evidence strategies across the product lifecycle. /li liWork closely with GVAP Asset Leads, Regional Access Leads, country access leads and HEOR to identify the evidence requirements necessary to support Joint Scientific Consultations (JSC), Joint Clinical Assessments (JCA), national HTA assessments, reimbursement submissions and pricing negotiations. /li liEvaluate trade-offs between evidence options and recommend risk mitigation strategies that optimise payer, access, pricing and development objectives. /li liEnsure access evidence requirements are embedded within Integrated Evidence Plans. /li /ul h3Influence On Clinical Development /h3 ul liIn close collaboration with GVAP Asset Leads and HEOR, provide expert market access and HTA input into clinical development programmes, registrational study design, comparator strategy, endpoint selection, patient population selection, subgroup evidence generation, PRO strategy and real-world evidence generation. /li liInfluence development decisions to proactively address future reimbursement risks rather than reacting to them post-approval. /li /ul h3U.S. Evidence Requirements Cross-Regional Reconciliation /h3 ul liServe as the standing point of contact to the U.S. Value Access, U.S. HEOR and U.S. Medical teams for pipeline evidence planning. /li liSystematically elicit, document and prioritise U.S. payer, PBM, IDN and employer evidence requirements — including comparator expectations, endpoint and subgroup needs, real-world data requirements, AMCP-format dossier inputs and ICER assessment risk — and ensure these are represented in Integrated Evidence Plans alongside EU HTA and other ex-U.S. requirements. /li liIdentify and elevate conflicts between U.S. and ex-U.S. evidence requirements (e.g. divergent comparators, populations, or endpoint hierarchies) with a recommended resolution and an articulated trade-off, rather than deferring the decision. /li liAnticipate the access implications of U.S. policy developments, including CMS price negotiation and Medicare/Medicaid coverage dynamics, and translate these into evidence-generation requirements at the point where development decisions are still open. /li /ul h3Value Demonstration Evidence Generation /h3 ul liDevelop and maintain asset-specific payer value demonstration plans. /li liShape, in tight collaboration with HEOR, evidence generation activities including cost-effectiveness analyses, budget impact models, RWE studies, PRO studies, long-term outcome analyses, indirect treatment comparisons and network meta-analyses. /li liCollaborate closely with HEOR and Medical Affairs teams to ensure evidence packages address stakeholder needs across global healthcare systems. /li /ul h3HTA Payer Landscape Monitoring /h3 ul liMaintain deep expertise on evolving global HTA methodologies and payer evidence expectations, monitoring changes in the EU HTA Regulation, NICE, HAS, G-BA/IQWiG, AIFA, CADTH, ICER and other major payer and assessment bodies. Such monitoring covers U.S. payer, PBM and value-assessment developments on the same footing as EU and other ex-U.S. bodies, with implications translated into concrete evidence requirements for U.S.-relevant programmes. /li liTranslate emerging requirements into actionable evidence-generation strategies. /li liEnsure assets are prepared for both EU-level and local HTA decision-making. /li /ul h3Value Proposition Payer Communication /h3 ul liSupport GVAP Asset Leads to develop compelling payer-focused value propositions. /li liEnsure clinical, economic and patient-centered evidence is translated into core value narratives, HTA dossiers, global value dossiers, pricing toolkits and reimbursement materials. /li liProvide expert input into key messages and evidence-based value stories supporting payer and HTA engagement. /li /ul h3External Engagement Capability Building /h3 ul liBuild and maintain relationships with HTA experts, policy experts and academic researchers. /li liRepresent the organisation in scientific and methodological discussions. /li liContribute to the advancement of access-related methodologies and evidence-generation best practices. /li liActively contribute to capability building and continuous improvement across GVAP. /li /ul h3Required Qualifications /h3 ul liMSc, MPH or equivalent advanced degree in health economics, epidemiology, public health, biostatistics, life sciences or health policy; PhD, PharmD or MD preferred, as is additional business or strategic leadership education. /li li8 + years of experience in market access, HEOR, value access or evidence strategy. /li liDemonstrated experience supporting HTA submissions, reimbursement negotiations, evidence planning and global launch preparation. /li liStrong understanding of EU HTA/JCA, RWE methodologies, economic modelling, clinical development and international payer decision-making. /li liProven ability to lead cross-functional and cross-regional initiatives and to influence without direct authority in a matrixed, global organization. /li liExcellent written and verbal communication skills in English. /li /ul h3Location Ways of Working /h3 pThis role can be based in Switzerland (Basel area). International travel is expected to support cross-functional and regional collaboration. Regular, scheduled engagement with U.S.-based Value Access, HEOR and Medical colleagues is a core requirement of the role. Whichever base location applies, the incumbent maintains sufficient overlap with both U.S. Eastern and Central European time zones to sustain a functioning two-way evidence-requirements loop. /p h3Travel: /h3 p15% of time. /p pSalary Range Switzerland: 198,200.00 CHF - 247,700.00 CHF /p h3Global Competencies /h3 ul liFosters Teamwork /li liProvides and Solicits Honest and Actionable Feedback /li liSelf-Awareness /li liActs Inclusively /li liDemonstrates Initiative /li liEntrepreneurial Mindset /li liContinuous Learning /li liEmbraces ChangeResults-Oriented /li liAnalytical Thinking/Data Analysis /li liFinancial Excellence /li liCommunicates with Clarity /li /ul pWe are proud to be an equal opportunity employer. BeOne does not discriminate on the basis of race, religion, color, sex, gender identity, sexual orientation, age, disability, national origin, veteran status or any other basis covered by appropriate law. All employment is decided on the basis of qualifications, merit, and business need. /p #J-18808-Ljbffr